TD Cowen Reaffirms “Buy” Rating for Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT)‘s stock had its “buy” rating reiterated by analysts at TD Cowen in a research report issued on Wednesday, Benzinga reports. They currently have a $110.00 price target on the medical technology company’s stock. TD Cowen’s price target suggests a potential upside of 26.20% from the stock’s current price.

A number of other brokerages have also weighed in on MDT. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Leerink Partners dropped their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Bank of America raised their target price on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Mizuho set a $115.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $103.92.

Medtronic Price Performance

MDT opened at $87.16 on Wednesday. The business has a fifty day moving average of $89.91 and a 200 day moving average of $84.79. The stock has a market cap of $111.49 billion, a P/E ratio of 21.47, a PEG ratio of 2.04 and a beta of 0.56. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business’s revenue was up 13.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts anticipate that Medtronic will post 5.98 EPS for the current year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MDT. Ipsen Advisor Group LLC boosted its stake in Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after purchasing an additional 101 shares during the period. Arlington Trust Co LLC increased its position in Medtronic by 11.6% in the 2nd quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after buying an additional 120 shares during the period. Bigelow Investment Advisors LLC lifted its holdings in shares of Medtronic by 1.1% during the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after buying an additional 121 shares during the last quarter. Bank & Trust Co boosted its position in shares of Medtronic by 2.8% in the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after acquiring an additional 121 shares during the period. Finally, Integrity Alliance LLC. boosted its position in shares of Medtronic by 1.7% in the second quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after acquiring an additional 125 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic was highlighted as a potentially inexpensive growth stock trading below $100, with the article pointing to attractive valuation, financial strength and future growth prospects. 3 Absurdly Cheap Growth Stocks That Are Trading Below $100
• Positive Sentiment: Medtronic’s medical-device business was included among historically stable dividend raisers, reinforcing the investment case based on recurring healthcare demand and shareholder distributions. Historically Stable Dividend Raisers in Medical Devices
• Positive Sentiment: Options activity was notably bullish in volume terms, with investors purchasing 29,587 call options—well above the typical volume cited in the report. However, options activity reflects positioning and is not a guarantee of future stock performance.
• Neutral Sentiment: Analyst coverage offered insights on Medtronic alongside another healthcare company, but the provided report details do not specify a material rating change or new price target. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Medtronic was listed among medical stocks that could potentially beat upcoming earnings estimates, but the article is focused on screening methodology rather than a confirmed forecast for Medtronic. Medical Stocks That Could Beat Earnings
• Negative Sentiment: The main market update reported that Medtronic fell more than the overall market, indicating near-term selling pressure. The report provides performance context but no specific operational problem or negative earnings revision. Medtronic Registers a Bigger Fall Than the Market

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.